Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Koehler

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Materia Medica Polona. Polish Journal of Medicine and Pharmacy|April 1, 1989
Evaluation of the cardiovascular system in children with simple obesity. Part II. Echocardiographic assessmentB Koehler, E Małecka-Tendera, B Drzewiecka, et al.
Journal of Neurosurgery|March 6, 1999
Integration of preoperative and intraoperative functional brain mapping in a frameless stereotactic environment for lesions near eloquent cortex. Technical noteJ D McDonald, B W Chong, J D Lewine, et al.
Haematologica|June 15, 2019
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single centerYucai Wang, Marcella A Tschautscher, Kari G Rabe, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 2, 2025
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemiaRachel J Bailen, Monica I Aasum, Linda M Tamminga, et al.
American Journal of Hematology|February 22, 2023
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b studyScott F Huntington, Stephen J Schuster, Wei Ding, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Blood Cancer Journal|August 6, 2021
Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic IndexYucai Wang, Sara J Achenbach, Kari G Rabe, et al.
American Journal of Hematology|August 24, 2023
Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatmentSamuel R Kosydar, Sameer A Parikh, Scott C Lester, et al.
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.
Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Materia Medica Polona. Polish Journal of Medicine and Pharmacy|April 1, 1989
Evaluation of the cardiovascular system in children with simple obesity. Part II. Echocardiographic assessmentB Koehler, E Małecka-Tendera, B Drzewiecka, et al.
Journal of Neurosurgery|March 6, 1999
Integration of preoperative and intraoperative functional brain mapping in a frameless stereotactic environment for lesions near eloquent cortex. Technical noteJ D McDonald, B W Chong, J D Lewine, et al.
Haematologica|June 15, 2019
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single centerYucai Wang, Marcella A Tschautscher, Kari G Rabe, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 2, 2025
A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemiaRachel J Bailen, Monica I Aasum, Linda M Tamminga, et al.
American Journal of Hematology|February 22, 2023
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b studyScott F Huntington, Stephen J Schuster, Wei Ding, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
Blood Cancer Journal|August 6, 2021
Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic IndexYucai Wang, Sara J Achenbach, Kari G Rabe, et al.
American Journal of Hematology|August 24, 2023
Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatmentSamuel R Kosydar, Sameer A Parikh, Scott C Lester, et al.
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.
Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.
Pageof 10